Request Trial
shutterstock_1935382585_valeriya_zankovych
Valeriya Zankovych / Shutterstock.com
9 March 2023FeaturesBiotechnologySarah Speight

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotechnology
Merck KGaA agrees $11.3bn deal in major life sciences expansion
26 June 2026   Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.
Biotechnology
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026   Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026   The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.


Editor's picks

Pfizer’s US Paxlovid patent fight turns on a single error
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026

Editor's picks

Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026

More features

Will Mounjaro and Zepbound get their first US generic rival?
Ashurst Perkins Coie opens its doors following landmark merger
Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Insilico lands potential $2.5bn AI biotech partnership
US life sciences damages averaged $33.5m between 2019-2025
Court upholds $83m sequencing verdict and sets royalty rate